The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:2389-2390 June 1, 2006 Number 22
NextNext

Thalidomide for Multiple Myeloma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Barlogie, B.
-PubMed Citation
To the Editor: Barlogie et al. (March 9 issue)1 report an increased response rate of multiple myeloma to thalidomide plus high-dose chemotherapy and transplantation. However, there was no difference in overall survival between the group that received thalidomide from the beginning of the study and the control group, which received thalidomide only after relapse.

The fact that no increase in survival was observed may be particular to the protocol of Barlogie et al., in which high-dose chemotherapy is given concurrently with thalidomide. This design amplifies drug-related toxicity and favors the emergence of tumor and stromal elements that are resistant to . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.